MYGN - ミリアド・ジェネティックス (Myriad Genetics Inc.)

MYGNのニュース

   Global Direct-to-Consumer Laboratory Testing Market (2021 to 2027) - Industry Analysis, Trends, Market Size and Forecasts - ResearchAndMarkets.com  2022/01/06 15:13:00 Kwhen Finance
   Myriad Genetics Inc. (NASDAQ:MYGN) Is Likely To Perform Well Over The Long Term. Lost Nearly -1.55% Last Month.  2021/12/24 15:00:00 Marketing Sentinel
In last trading session, Myriad Genetics Inc. (NASDAQ:MYGN) saw 0.29 million shares changing hands with its beta currently measuring 1.57. Company’s recent per share price level of $27.29 trading at $0.26 or 0.96% at ring of the bell on the day assigns it a market valuation of $2.11B. That closing price of MYGN’s stock is … Myriad Genetics Inc. (NASDAQ:MYGN) Is Likely To Perform Well Over The Long Term. Lost Nearly -1.55% Last Month. Read More »
   Maryland State Retirement & Pension System Buys Shares of 30,571 Myriad Genetics, Inc. (NASDAQ:MYGN)  2021/12/23 10:26:42 Transcript Daily
Maryland State Retirement & Pension System purchased a new position in Myriad Genetics, Inc. (NASDAQ:MYGN) during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund purchased 30,571 shares of the company’s stock, valued at approximately $1,009,000. Several other large investors have also recently modified their holdings […]
   $162.25 Million in Sales Expected for Myriad Genetics, Inc. (NASDAQ:MYGN) This Quarter  2021/12/22 09:26:41 Transcript Daily
Wall Street brokerages forecast that Myriad Genetics, Inc. (NASDAQ:MYGN) will post sales of $162.25 million for the current quarter, according to Zacks Investment Research. Four analysts have issued estimates for Myriad Genetics earnings. The highest sales estimate is $168.37 million and the lowest is $157.52 million. Myriad Genetics posted sales of $154.60 million in the []
   Global Direct-to-Consumer Laboratory Testing Market (2021 to 2027) - Industry Analysis, Trends, Market Size and Forecasts - ResearchAndMarkets.com  2022/01/06 15:13:00 Kwhen Finance
   Myriad Genetics Inc. (NASDAQ:MYGN) Is Likely To Perform Well Over The Long Term. Lost Nearly -1.55% Last Month.  2021/12/24 15:00:00 Marketing Sentinel
In last trading session, Myriad Genetics Inc. (NASDAQ:MYGN) saw 0.29 million shares changing hands with its beta currently measuring 1.57. Company’s recent per share price level of $27.29 trading at $0.26 or 0.96% at ring of the bell on the day assigns it a market valuation of $2.11B. That closing price of MYGN’s stock is … Myriad Genetics Inc. (NASDAQ:MYGN) Is Likely To Perform Well Over The Long Term. Lost Nearly -1.55% Last Month. Read More »
   Maryland State Retirement & Pension System Buys Shares of 30,571 Myriad Genetics, Inc. (NASDAQ:MYGN)  2021/12/23 10:26:42 Transcript Daily
Maryland State Retirement & Pension System purchased a new position in Myriad Genetics, Inc. (NASDAQ:MYGN) during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund purchased 30,571 shares of the company’s stock, valued at approximately $1,009,000. Several other large investors have also recently modified their holdings […]
   $162.25 Million in Sales Expected for Myriad Genetics, Inc. (NASDAQ:MYGN) This Quarter  2021/12/22 09:26:41 Transcript Daily
Wall Street brokerages forecast that Myriad Genetics, Inc. (NASDAQ:MYGN) will post sales of $162.25 million for the current quarter, according to Zacks Investment Research. Four analysts have issued estimates for Myriad Genetics earnings. The highest sales estimate is $168.37 million and the lowest is $157.52 million. Myriad Genetics posted sales of $154.60 million in the []
   The Daily Biotech Pulse: Merck's Keytruda Gets Label Expansion In Europe, Pfizer To Sell Chinese Biologics Unit, Celcuity Spikes  2021/03/17 11:43:07 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs March 16) Affimed N.V. (NASDAQ: AFMD ) BioAtla, Inc. (NASDAQ: BCAB ) Champions Oncology, Inc. (NASDAQ: CSBR ) Harvard Bioscience, Inc. (NASDAQ: HBIO ) Myriad Genetics, Inc. (NASDAQ: MYGN ) Omnicell, Inc. (NASDAQ: OMCL ) Savara Inc. (NASDAQ: SVRA ) (reacted to a positive analyst action and insider buying) Sierra Oncology, Inc. (NASDAQ: SRRA ) Sol-Gel Technologies Ltd. (NASDAQ: SLGL ) Vincerx Pharma, Inc. (NASDAQ: VINC ) Down In The Dumps (Biotech Stocks Hitting 52-week Lows March 16) Galecto, Inc. (NASDAQ: GLTO ) Immunocore Holdings plc (NASDAQ: IMCR ) Stocks In Focus Pfizer to Sell Chinese Biologics Unit to WuXi Pfizer Inc.'s (NYSE: PFE ) China unit and Hong Kong-listed WuXi Biologics announced an equity agreement under which the latter will acquire the former's state-of-the-art biologics manufacturing facilities as well as its labor force in Hangzhou, China.
   Cancer Biomarkers Market US$ 31,206.00 Mn in 2027 with QIAGEN, bioMérieux, Inc., Creative Diagnostics, Hologic Inc., Quest Diagnostics, Myriad Genetics, Inc.  2021/03/02 13:28:32 OpenPR
Cancer Biomarkers Market research report delivers a comprehensive study on production capacity, consumption, import and export for all major regions across the world. Report provides is a professional inclusive study on the current state for the market. Analysis and discussion
   The Daily Biotech Pulse: Adcom Test Awaits J&J's COVID-19 Vaccine, Lilly To Supply Additional Antibody Therapy Doses To US, Regulatory Setback For Tricida  2021/02/26 13:16:52 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Feb. 25) Apyx Medical Corp (NASDAQ: APYX ) Aslan Pharmaceuticals Ltd (NASDAQ: ASLN ) (announced an $18-million private placement) Bioatla Inc (NASDAQ: BCAB ) Dicerna Pharmaceuticals Inc (NASDAQ: DRNA ) Five Prime Therapeutics Inc (NASDAQ: FPRX ) Glaukos Corp (NYSE: GKOS ) Myriad Genetics, Inc. (NASDAQ: MYGN ) Organogenesis Holdings Inc (NASDAQ: ORGO ) Pacira Biosciences Inc (NASDAQ: PCRX ) (announced fourth-quarter results) Pandion Therapeutics Inc (NASDAQ: PAND ) - announced a deal to be bought by Merck & Co., Inc. (NYSE: MRK ) for $1.85 billion Pliant Therapeutics Inc (NASDAQ: PLRX ) Vanda Pharmaceuticals Inc. (NASDAQ: VNDA ) Down In The Dumps (Biotech Stocks Hitting 52-week Lows Feb. 25) Acutus Medical Inc (NASDAQ: AFIB ) Aptose Biosciences Inc (NASDAQ: APTO ) Bioventus Class A Ord Shs (Proposed) (NASDAQ: BVS ) Epizyme Inc (NASDAQ: EPZM ) Intercept Pharmaceuticals Inc (NASDAQ: ICPT ) (reacted to fourth-quarter results) Lucira Health Inc (NASDAQ: LHDX ) Opthea Spon American Depositary Receipts Representing 8 Ord Shs (NASDAQ: OPT ) Sensei Biotherapeutics Inc (NASDAQ: SNSE ) Virios Therapeutics LLC (NASDAQ: VIR ) Voyager Therapeutics Inc (NASDAQ: VYGR ) Stocks In Focus Tricida Receives Appeals Denied Letter From FDA Regarding Veverimer Tricida Inc (NASDAQ: TCDA ) said it has received an appeal denied letter, or ADL, from the FDA's Office of New Drugs in response to a formal dispute resolution request submitted in December regarding its NDA for veverimer, which is being evaluated as a treatment option for metabolic acidosis in chronic kidney disease patients.
   Cancer Biomarkers Market to Set Phenomenal Growth from 2021 to 2026| Becton, Agilent Technologies, Biomerieux, Myriad Genetics  2021/02/23 13:00:26 OpenPR
Global Cancer Biomarkers Market Report 2021 is latest research study released by HTF MI evaluating the market, highlighting opportunities, risk side analysis, and leveraged with strategic and tactical decision-making support. The study provides information on market trends and development, drivers,
   Myriad Genetics Analysts Are Pretty Bullish ... Stock market Insights & financial analysis  2021/02/22 17:30:00 Stock Market Daily
Myriad Genetics announce their quarterly, annual earnings. See the latest EPS estimates. Listen to the conference call and remind yourself by…

calendar